In summary, our findings suggest that HDAC6 is positively associated with cisplatin resistance in NSCLC and reveal HDAC6 as a potential novel therapeutic target for platinum refractory NSCLC. This evidence concerns the gene HDAC6 and non-small cell lung carcinoma.